Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients

Abstract Background Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between non-small cell lung cancer (NSCLC) patients with varied resp...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu, Shenglin Ma, Jia Huang, Tianxiang Chen, Ziming Li, Wenxiang Ji, Liwei Song, Lan Shen, Long Jiang, Zicheng Yu, Chao Zhang, Zaixian Tai, Changxi Wang, Rongrong Chen, David P. Carbone, Xuefeng Xia, Shun Lu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-05-01
coleção:	Journal of Hematology & Oncology
Assuntos:	Whole-exome sequencing Homologous recombination deficiency Neoadjuvant immunotherapy NSCLC Biomarker
Acesso em linha:	https://doi.org/10.1186/s13045-022-01283-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!